On January 6, 2023 Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells, reported that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th (Press release, Phio Pharmaceuticals, JAN 6, 2023, View Source [SID1234625974]). The Dermatology Summit is taking place at the Hyatt Regency, alongside the annual JPMorgan Healthcare Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Logo – View Source

Mr. Bitterman will discuss innovations in dermatological cancers, highlighting Phio’s proprietary INASTYL platform. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics.

Mr. Bitterman was recently appointed to his leadership role at Phio. He previously led Cutanea and Dermik in the development and commercialization of small molecule dermatological products.